In the claims

1-26. **(canceled)**

27. **(currently amended)** A compound represented by formula **(II):**



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, and heteroaryl~~, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~;

R_3-R_{13} are ~~each independently are selected from the group consisting of~~ hydrogen~~, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, $-C(O)R_{15}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, $-N_3$, $-C(R_{15})=NR_{15}$, $-N=C(R_{15})_2$, $-C(O)N(R_{15})_2$, $-Q_2-P(Q_1)(OR_{15})_2$, $-SO_2R$, silyl, $-R_{16}OR_{15}$, $-SR_{15}$, and $-CO_2R_{15}$~~;

R_{14} is selected from the group consisting of $-R_{16}C(O)OR_{15}$, $-OC(O)R_{15}$, [[$-O-R_{17}$]] $-O-R_{17}$, wherein R_{17} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; $-R_{16}(O)CR_{15}$; $-C(R_{15})=N(OH)$; carboxylic acid; $-R_{16}C(O)H$; $-Q_2-P(Q_1)(OR_{15})_2$; and silyl;

R_{15} represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_{16} represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_{15};

or a pharmaceutically acceptable salt thereof.

28. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl,~~ and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~, and R_1 is hydrogen~~, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl~~; and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$.

29. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_1 is hydrogen.

30. **(currently amended)** The compound of claim 27, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl, and substituted or unsubstituted alkenylaryl; and R_2 is hydrogen~~, and the compound is an E (entgegen) isomer~~.

31. **(currently amended)** The compound of claim 27, wherein R_1 is 4-methoxy-phenyl, R_2 is hydrogen, ~~R_3-R_{13} each represent hydrogen,~~ and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$.

32. **(currently amended)** The compound of claim 27, wherein R_1 is phenyl, R_2 is hydrogen, ~~R_3-R_{13} each represent hydrogen,~~ and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$.

33. **(currently amended)** A pharmaceutical composition comprising a compound of formula **(II):**



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, and heteroaryl~~, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~;

R_3-R_{13} are ~~each independently are selected from the group consisting of~~ hydrogen~~, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, $-C(O)R_{15}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, N_3, $-C(R_{15})=NR_{15}$, $-N=C(R_{15})_2$, $-C(O)N(R_{15})_2$, $-Q_2-P(Q_1)(OR_{15})_2$, $-SO_2R$, silyl, $-R_{16}OR_{15}$, $-SR_{15}$, and $-CO_2R_{15}$~~;

R_{14} is selected from the group consisting of $-R_{16}C(O)OR_{15}$, $-OC(O)R_{15}$, ~~[[O-R_{17}]]~~ -O-R_{17}, wherein R_{17} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; $-R_{16}(O)CR_{15}$; $-C(R_{15})=N(OH)$; carboxylic acid; $-R_{16}C(O)H$; $-Q_2-P(Q_1)(OR_{15})_2$; and silyl;

R_{15} represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_{16} represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_{15};

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.

34. **(currently amended)** The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl,~~ and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~, and R_1 is hydrogen~~, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl~~; and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$.

35. **(currently amended)** The pharmaceutical composition of claim 33, wherein R_1 is selected from the group consisting of haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_2 is hydrogen; or R_2 is selected from the group consisting of haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_1 is hydrogen.

36. **(currently amended)** The pharmaceutical composition of claim 33, The compound of claim 27, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl~~, and substituted or unsubstituted alkenylaryl~~; and R_2 is hydrogen~~, and the compound is an E (entgegen) isomer~~.

37. **(currently amended)** A method for treating a disorder caused by a deficiency in monoamine concentration in a human comprising administering a therapeutically effective dose of a compound of formula **(II)**:



(II)

wherein,

R_1 and R_2 each independently are selected from the group consisting of hydrogen, aryl, and heteroaryl~~, cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~;

R_3-R_{13} are ~~each independently are selected from the group consisting of~~ hydrogen~~, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, polycyclic, heterocyclic, alkoxy, $-C(O)R_{15}$, amino, hydroxy, thio, halogen, cyano, nitro, trifluoromethyl, $-N_3$, $-C(R_{15})=NR_{15}$, $-N=C(R_{15})_2$, $-C(O)N(R_{15})_2$, $-Q_2-P(Q_1)(OR_{15})_2$, $-SO_2R$, silyl, $-R_{16}OR_{15}$, $-SR_{15}$, and $-CO_2R_{15}$~~;

R_{14} is selected from the group consisting of $-R_{16}C(O)OR_{15}$, $-OC(O)R_{15}$, [[O-R_{17}]] -O-R_{17}, wherein R_{17} is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, and alkynyl; $-R_{16}(O)CR_{15}$; $-C(R_{15})=N(OH)$; carboxylic acid; $-R_{16}C(O)H$; $-Q_2-P(Q_1)(OR_{15})_2$; and silyl;

R_{15} represents independently for each occurrence hydrogen, alkyl, alkenyl, alkynyl, or aryl;

R_{16} represents independently for each occurrence a bond or an alkyl, alkenyl, alkynyl, or aryl biradical;

Q_1 represents independently for each occurrence S or O; and

Q_2 represents independently for each occurrence O, S, or NR_{15};

or a pharmaceutically acceptable salt thereof.

38. (**currently amended**) The method of claim 37, wherein R_1 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl,~~ and R_2 is hydrogen, or R_2 is selected from the group consisting of aryl, and heteroaryl, ~~cycloalkyl, polycyclic, heterocyclic, alkenyl, and alkynyl~~, and R_1 is hydrogen~~, and the compound is an E (entgegen) or Z (zusammen) isomer; R_3-R_{13} each independently represent hydrogen or alkyl~~; and R_{14} is $-R_{16}C(O)OR_{15}$ or $-OC(O)R_{15}$.

39. (**currently amended**) The method of claim 37, wherein R_1 is selected from the group consisting of haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_2 is hydrogen; or R_2 is selected from the group consisting of

haloaryl, and alkylaryl~~, polycyclyl, alkenylaryl, and alkynylaryl~~; and R_1 is hydrogen.

40. **(currently amended)** The method of claim 37, wherein R_1 is selected from the group consisting of phenyl, 3,4-Dichloro-phenyl, 4-methoxy-phenyl, 4-fluoro-phenyl, 1-napthyl, 2-furyl, 3-furyl~~, nd substituted or unsubstituted alkenylaryl~~; and R_2 is hydrogen, and the compound is an E (entgegen) isomer.

41. **(previously presented)** The method of claim 37, wherein said disorder in a human is associated with a deficiency in the concentration of serotonin or norepinephrine.

42. **(previously presented)** The method of claim 37, wherein said disorder in a human is selected from the group consisting of depression, substance addiction, neurodegenerative disease, Attention Deficit Disorder, Huntington's Disease, and bipolar disorder.

43. **(previously presented)** The method of claim 42, wherein said disorder in a human is Parkinson's Disease or Alzheimer's Disease.

44. **(previously presented)** The method of claim 42, wherein said substance addiction is cocaine addiction.

45-59. **(canceled)**